News
19h
News-Medical.Net on MSNVCU Massey pioneers clinical trial of novel GGT-1 inhibitor PTX-100VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical ...
New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK ...
The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.
1d
Zacks Investment Research on MSNRXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug ...
Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...
The new drug forces fat cells to produce more energy and doesn't impact appetite or muscle mass, unlike some existing ...
TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...
Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...
Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...
TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a ...
At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results